Vilon (Lys-Glu dipeptide) is a synthetic peptide bioregulator originally developed as a geroprotective compound targeting the vascular system and connective tissue. Unlike anabolic or androgenic compounds, Vilon works through gene expression modulation in endothelial and smooth muscle cells, normalizing vascular tone, enhancing microcirculation, and supporting immune function through chromatin interaction.
This protocol guide is designed for individuals considering Vilon supplementation based on published research from Russian clinical trials and mechanistic studies. This is educational content only and does not constitute medical advice. Always consult a qualified healthcare provider before beginning any peptide protocol, especially if you have existing cardiovascular, metabolic, or immune conditions.
Key Facts:
- Compound Class: Short peptide bioregulator (2 amino acids)
- Primary Target Tissues: Vascular endothelium, smooth muscle, immune cells
- Mechanism: Nuclear penetration and chromatin modulation; gene expression regulation
- Approved Status: Research compound only; not FDA/EMA approved
- Purity Risk: Highly variable across vendors; purchase only from verified, third-party tested sources
Injection Protocol (Most Common)
Dose Range: 0.1–1 mcg once daily via subcutaneous or intramuscular injection
Standard Starting Dose: 0.5 mcg daily
Typical Cycle Length: 10–30 days continuous, followed by 1–3 weeks off
Frequency: 6 cycles per year (rotating 10–30 days on, 14–21 days off) for long-term use
Reconstitution (if freeze-dried):
- Use sterile bacteriostatic water or 0.9% saline
- Inject water slowly into vial to avoid foaming
- Let peptide dissolve for 2–5 minutes at room temperature
- Solution should be clear; do not use if cloudy or discolored
- Store reconstituted solution at 2–8°C (refrigerated); use within 14 days
Injection Sites: Rotate between subcutaneous sites on abdomen, thigh, or upper arm to minimize local irritation. Do not inject into the same site more than twice per week.
Sublingual Protocol (Alternative)
Dose Range: 1–2 mcg once daily, placed under the tongue
Standard Starting Dose: 1 mcg daily
Administration: Place powder or tablet sublingually for 1–2 minutes before swallowing; do not eat or drink for 15 minutes before or after
Cycle Length: 10–30 days on, 14–21 days off (same as injection)
Note: Sublingual absorption is less reliable and has limited clinical evidence compared to injection; injection is preferred for consistent bioavailability.
Protocol A: Immune & Longevity Support (Most Evidence)
Target Outcome: Normalize immune function, improve vascular aging markers, support metabolic health
Cycle Structure:
- Days 1–10: 0.5 mcg daily (injection) or 1 mcg daily (sublingual)
- Days 11–20: 0.3 mcg daily (injection only; reduce on day 11 to prevent receptor downregulation)
- Days 21–30: Rest period
Repeat: 6–8 cycles per year
Rationale: Human RCT evidence shows T-cell normalization and reduced insulin requirements in diabetic patients. Lower doses in week 2 prevent potential immune overstimulation from continuous signaling.
Monitoring: If you have metabolic disorders (diabetes, prediabetes), monitor blood glucose, insulin requirements, and T-cell counts (if possible) before and after a 30-day cycle.
Protocol B: Vascular & Connective Tissue Health
Target Outcome: Improve microcirculation, normalize vascular tone, support tissue regeneration
Cycle Structure:
- Days 1–21: 0.5 mcg daily (injection)
- Days 22–35: Rest
Repeat: 5–6 cycles per year
Extended Option:
- Days 1–14: 0.5 mcg daily
- Days 15–21: 0.7 mcg daily (dose escalation week)
- Days 22–35: Rest
Rationale: Vilon's primary mechanism targets vascular tissue. Extended 21-day cycles allow sustained gene expression modulation in endothelial cells before rest. Extended option adds mild escalation to activate stronger vascular remodeling in final week.
Monitoring: Track resting heart rate, blood pressure (if hypertensive), and any improvements in circulation (reduced cold hands/feet, improved endurance during activity).
Protocol C: Stress Resilience & Mood Support
Target Outcome: Reduce hypothalamic activation to stress, improve emotional resilience
Cycle Structure:
- Days 1–14: 0.3 mcg daily (injection) — lower dose for CNS-sensitive individuals
- Days 15–28: 0.5 mcg daily
- Days 29–42: Rest
Repeat: 4–6 cycles per year
Rationale: Animal evidence shows Vilon reduces IL-2-positive neurons in stress-responsive hypothalamic regions. Graduated dosing allows CNS adaptation without overstimulation.
Monitoring: Log mood, sleep quality, and stress response over 2–3 cycles. Effects typically begin after 7–10 days.
Protocol D: Energy & Mitochondrial Support
Target Outcome: Enhance cellular energy production, reduce oxidative stress
Cycle Structure:
- Days 1–7: 0.3 mcg daily
- Days 8–21: 0.5 mcg daily
- Days 22–35: Rest
Repeat: 6–8 cycles per year (can stack with immune protocol)
Rationale: Vilon inhibits mitochondrial ROS generation. Longer cycles (21 days) optimize mitochondrial enzyme expression before rest.
Monitoring: Track energy levels, fatigue resistance during exercise, and recovery time between workouts.
Protocol E: Skin & Hair Health
Target Outcome: Support collagen expression and cellular senescence reversal in fibroblasts
Cycle Structure:
- Days 1–30: 0.5 mcg daily (injection) or 2 mcg daily (sublingual)
- Days 31–45: Rest
Repeat: 4–5 cycles per year
Note: In-vitro evidence shows 83% increased collagen type I in aged fibroblasts; human efficacy is unproven.
Monitoring: Take baseline skin photos. Reassess after 2–3 cycles (8–12 weeks) for texture, firmness, or elasticity changes.
Injection Administration
Required Materials:
- Sterile insulin syringe (29–31 gauge, 0.3–0.5 mL)
- Alcohol prep pads
- Sharps container
- Reconstituted Vilon solution (if freeze-dried)
Procedure:
- Prepare: Wash hands thoroughly. If Vilon is freeze-dried, reconstitute 2–4 hours before injection using sterile water.
- Draw: Holding the vial upright, insert the needle. Pull back the plunger to draw the correct dose (e.g., 0.5 mcg).
- Prepare Site: Select a subcutaneous site on the abdomen, thigh, or upper arm. Cleanse the area with an alcohol pad using a circular motion; let dry for 10 seconds.
- Inject: Pinch the skin gently. Insert the needle at a 45–90-degree angle (45° for thinner skin areas). Push the plunger slowly to inject the peptide over 3–5 seconds.
- Withdraw: Remove the needle and gently press the injection site with a clean pad for 10 seconds. Do not rub.
- Dispose: Place the syringe immediately into a sharps container.
Timing: Inject at the same time daily (morning or evening). Consistency improves outcomes.
Sublingual Administration
Required Materials:
- Vilon powder or tablet
- Clean tongue
Procedure:
- Place the dose (1–2 mcg powder or tablet) under the tongue
- Hold for 1–2 minutes; allow to dissolve
- Avoid swallowing saliva until 1–2 minutes have passed
- Do not eat or drink for 15 minutes before or after
Note: Sublingual administration has weaker evidence; injections are preferred.
Goal: General immune support and geroprotection (Protocol A)
| Week | Injection Dose | Expected Effects | Notes |
|---|
| 1 | 0.5 mcg daily | Mild baseline effects; possible injection site redness | Establish routine; monitor for adverse reactions |
| 2 | 0.5 mcg daily | Potential lightheadedness (vascular effect); improved sense of wellbeing | Some users report increased alertness |
| 3 | 0.3 mcg daily (reduced) | Effects sustain; fatigue may subside if experienced | Dose reduction prevents immune overstimulation |
| 4 (Days 29–30) | 0.3 mcg daily | Consolidation phase; cumulative immune modulation | Begin 2–3 week rest period on Day 31 |
| Weeks 5–6 | 0 mcg (rest) | Receptor sensitivity resets; natural immune recovery | No injection during rest period |
Days 1–3:
- Local injection site redness or mild irritation (common)
- Possible transient lightheadedness (2–10 minutes post-injection), likely vascular-related
- No systemic effects yet
Days 4–7:
- Lightheadedness typically resolves as the body adapts
- Mild fatigue or lethargy possible in initial days (reported in ~10% of users)
- Some report improved mood or reduced stress reactivity (anecdotal)
Days 7–14:
- Immune modulation begins; T-cell normalization (if measurable via lab)
- Improved sense of energy or endurance (variable; more noticeable in older individuals)
- Vascular effects: potential improvement in circulation, reduced cold extremities
Days 15–21:
- Peak bioregulatory effects on gene expression
- Cumulative benefits on microcirculation and connective tissue
- Sleep quality may improve (anecdotal reports)
Days 22–30:
- Sustained benefits; body adapts to peptide signaling
- Dose reduction (if applied) prevents overstimulation
- By end of cycle, effects plateau; rest period recommended
Rest Period (Days 31–42+):
- Peptide is cleared; no persistent effects
- Baseline immune function returns
- Receptor sensitivity resets, preparing for next cycle
Full Cycle Response (8–12 Weeks):
- Most significant improvements occur across 2–3 complete 30-day cycles
- Vascular and immune benefits compound with repeated cycles
- Longevity markers (if measured: coagulation factors, T-cell counts) show improvement in individuals with baseline dysfunction
Mistake 1: Continuous Dosing Without Rest Periods
- Error: Running Vilon 365 days per year without breaks
- Consequence: Receptor downregulation; diminished efficacy over time; potential immune dysregulation
- Fix: Always include 14–21 day rest periods between cycles
Mistake 2: Exceeding Recommended Doses
- Error: Injecting >1 mcg daily thinking "more is better"
- Consequence: Increased injection site reactions; potential overstimulation of cell proliferation (theoretical risk with long-term high-dose use); no additional benefit
- Fix: Stay within 0.5–1 mcg daily range; start at 0.3–0.5 mcg and titrate up only if needed
Mistake 3: Inconsistent Administration Timing
- Error: Injecting at different times each day or skipping days
- Consequence: Suboptimal gene expression modulation; inconsistent results
- Fix: Inject at the same time daily (morning or evening) for 10–30 consecutive days per cycle
Mistake 4: Using Reconstituted Solution Beyond 14 Days
- Error: Storing reconstituted peptide in refrigerator for 3+ weeks
- Consequence: Peptide degradation; reduced bioactivity; contamination risk
- Fix: Use reconstituted solution within 14 days; reconstitute fresh batches if needed
Mistake 5: Stacking with Multiple Immune-Modulating Peptides
- Error: Running Vilon + Thymosin + Fractalkine simultaneously
- Consequence: Unpredictable immune stimulation; potential autoimmune flare in susceptible individuals
- Fix: Run one immune-modulating peptide per cycle; separate by 4+ weeks if stacking multiple peptides
Mistake 6: Poor Vendor Selection
- Error: Purchasing from unverified suppliers without third-party testing
- Consequence: Contaminated, underdosed, or mislabeled product; health risk
- Fix: Only purchase from vendors with third-party COA (Certificate of Analysis) and verified customer reviews
Vilon's mechanism (gene expression modulation via nuclear penetration) is orthogonal to anabolic or androgenic compounds. Stacking is possible but requires careful planning.
Stack 1: Vilon + Thymosin Alpha-1 (Immune Enhancement)
- Vilon: 0.5 mcg daily (Days 1–20)
- Thymosin Alpha-1: 500 mcg 3x weekly (Days 1–20)
- Rationale: Both enhance T-cell function through different pathways; Vilon modulates gene expression while Thymosin is a direct immune activator
- Risk: Potential over-stimulation of immune system; not recommended for individuals with autoimmune conditions
- Separation: Run each peptide independently in separate cycles if concerned
Stack 2: Vilon + BPC-157 (Tissue Regeneration + Vascular Support)
- Vilon: 0.5 mcg daily (injection)
- BPC-157: 250 mcg daily (injection or oral)
- Rationale: Synergistic on connective tissue; BPC-157 accelerates healing while Vilon optimizes vascular support
- Risk: Minimal; mechanisms are complementary
- Cycle: 20 days on both; 21 days off
Stack 3: Vilon + NAD+ Booster (Energy + Longevity)
- Vilon: 0.5 mcg daily
- NMN or NR: 500–1000 mg daily (oral)
- Rationale: Vilon upregulates SIRT1; exogenous NAD+ precursors amplify SIRT pathway activation
- Risk: Low; complementary mechanisms
- Cycle: 30 days continuous; can repeat without extended breaks if monitoring liver function
Stack 4: Vilon + Epithalon (Longevity + Telomerase Support)
- Vilon: 0.5 mcg daily (10–20 days)
- Epithalon: 10 mg daily (10–20 days)
- Rationale: Both target cellular aging; Epithalon activates telomerase while Vilon modulates geroprotective gene expression
- Risk: Theoretical concern about excessive telomerase activation; limit frequency to 2–3 cycles per year
- Cycle: 14–20 days on both; 30+ days off
Stack 5: Vilon + Metformin (Metabolic Health — Advanced)
- Vilon: 0.5 mcg daily (injection)
- Metformin: 500 mg twice daily (oral; prescription)
- Rationale: Vilon reduces insulin requirements (per human RCT); metformin improves insulin sensitivity; synergistic for metabolic control
- Risk: Hypoglycemia if insulin-dependent; requires medical supervision
- Cycle: 20–30 days; must monitor blood glucose if diabetic
General Stacking Guidelines:
- Never stack Vilon with other vascular-modulating peptides (Melanotan II, etc.) due to potential additive cardiovascular effects
- Avoid stacking with immunosuppressive compounds (corticosteroids, azathioprine)